PDCD1 and neoplasm: For example, combinatorial targeting of hsa_circ_0076092 with PD-1 blockade synergistically disrupts the miR-744-5p/SLC7A5 immunosuppressive axis, resulting in greater tumor growth inhibition than monotherapy (144).